The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of sotatercept as a treatment for adults with pulmonary arterial hypertension (PAH). The FDA has given the application priority review, shortening the review time from the usual 10 months to six months. A decision…
Read more
This column describes the author’s own experiences with some prescription and over-the-counter drugs. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. When I was in college, I always had a Ricola cough drop on hand. They littered my…
Amid ongoing litigation, the U.S. Food and Drug Administration (FDA) has agreed to review an application from Liquidia that seeks to extend the approval of Yutrepia — an inhaled dry powder formulation of treprostinil — to cover pulmonary hypertension associated with interstitial lung disease (PH-ILD). The FDA in 2021…
Corsair Pharma has secured $23 million in financing to support clinical testing of a skin patch for the delivery of treprostinil to treat pulmonary arterial hypertension (PAH), the company announced. The transdermal patch is intended to provide continuous and consistent levels of treprostinil, similar to those achieved with…
With the change of seasons and the current Self-Improvement Month, columnist Jen Cueva plans to let go of what no longer serves her.
Visit the Pulmonary Hypertension News forums to connect with others in the PH community.
Messaging from our advertising partners.
Get regular updates to your inbox.
